RTP Mobile Logo
Virtual Molecular Tumor Board: Recognition and Management of Targetable Tumor Mutations in Less Common Cancer Types (Webinar Proceedings)
Released October 2020

Proceedings from the third in a 3-part webinar series. Featuring slide presentations and related discussion from Drs Marcia S Brose, Andrew McKenzie and Milan Radovich. (Video Program)

CE Information and Faculty Disclosures

    This activity is intended for medical oncologists, hematology-oncology fellows, pathologists and other allied healthcare professionals involved in the treatment of lung cancer and other solid tumors.


    • Recognize the spectrum and prevalence of potentially targetable genomic alterations in patients with thyroid cancer, cholangiocarcinoma and gastrointestinal stromal tumors (GIST), and discuss the means by which these alterations contribute to tumor growth and proliferation.
    • Recall FDA-approved and guideline-endorsed diagnostic platforms for biomarker testing in patients with advanced thyroid cancer, cholangiocarcinoma and GIST.
    • Refine clinical testing algorithms by assessing the advantages and disadvantages of available assays, including their capacity to accurately identify various genomic abnormalities.
    • Recollect new and emerging biomarkers for treatment (eg, mTOR gain of function, RET fusions, NTRK fusions, FGFR fusions, PDGFRA mutations, BAP1 mutations) for advanced thyroid cancer, cholangiocarcinoma and GIST.
    • Develop an understanding of and explore available data investigating established and investigational tumor driver mutations and the clinical activity of biomarker-based treatments for thyroid cancer, cholangiocarcinoma and GIST.
    • Integrate available and emerging novel therapies into treatment decision-making based on the findings from genomic analyses for patients with thyroid cancer, cholangiocarcinoma or GIST.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Marcia S Brose, MD, PhD
    Director, Center for Rare Cancers and Personalized Therapy
    Abramson Cancer Center
    Department of Medicine, Division of Hematology/Oncology
    Department of Otorhinolaryngology: Head and Neck Surgery
    Philadelphia, Pennsylvania

    Consulting Agreements and Contracted Research: Blueprint Medicines, Exelixis Inc, Lilly, Loxo Oncology Inc, a wholly subsidiary of Eli Lilly & Company.

    Andrew McKenzie, PhD
    Director, Personalized Medicine
    Sarah Cannon Research Institute
    Nashville, Tennessee

    No financial interests or affiliations to disclose.

    Milan Radovich, PhD
    Associate Professor
    IU Health Vice President for Oncology Genomics
    Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana

    Contracted Research: Boston Biomedical Inc, Lilly; Ownership Interest: Immunomedics Inc, LifeOmic Health LLC, Tyme Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Release date: October 2020
    Expiration date: October 2021

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Part 1: Molecular Tumor Board

Part 2: New Molecular Targets in Thyroid Cancer

Part 3: Targeting the FGFR Signaling Pathway in Cholangiocarcinoma

Part 4: New Options in the Management of GIST Harboring PDGFR Mutations

Part 5: Molecular Tumor Board (Continued)

Select Publications